Published in Eur J Heart Fail on April 05, 2013
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation (2016) 1.87
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol (2017) 1.40
Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J (2013) 1.08
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail (2014) 0.98
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail (2013) 0.96
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J (2015) 0.87
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail (2016) 0.87
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail (2016) 0.85
New medical therapies for heart failure. Nat Rev Cardiol (2015) 0.83
Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant (2014) 0.83
Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta (2014) 0.81
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vasc Health Risk Manag (2015) 0.80
Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J (2016) 0.78
The effect of captopril and losartan on the electrophysiology of myocardial cells of myocardial ischemia rats. Int J Clin Exp Med (2014) 0.78
The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function. BMC Res Notes (2016) 0.78
Sacubitril/Valsartan. Hosp Pharm (2015) 0.77
PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure? J Geriatr Cardiol (2015) 0.77
Novel drug targets in clinical development for heart failure. Eur J Clin Pharmacol (2014) 0.76
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail (2016) 0.76
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart (2016) 0.76
Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol (2016) 0.75
Novel approaches for treating hypertension. F1000Res (2017) 0.75
Critical Questions about PARADIGM-HF and the Future. Acta Cardiol Sin (2016) 0.75
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Des Devel Ther (2016) 0.75
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail (2016) 0.75
Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. Heart Fail Clin (2014) 0.75
End points in heart failure-are we doing it right? Eur J Clin Pharmacol (2017) 0.75
Novel drug mechanisms in development for heart failure. Pflugers Arch (2014) 0.75
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci (1981) 6.39
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol (2000) 6.08
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 3.39
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J (1998) 2.30
The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol (1992) 2.21
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol (2009) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens (2004) 1.90
Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail (2001) 1.78
Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol (2000) 1.50
Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med (2011) 1.30
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail (2009) 1.09
Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet (1989) 1.03
Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation (1994) 0.99
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol (2007) 0.96
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail (2004) 0.92
The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol (2000) 0.91
Role of endogenous atrial natriuretic factor in acute congestive heart failure. J Clin Invest (1989) 0.91
Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. Eur Heart J (1996) 0.90
Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol (2003) 0.88
CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail (2011) 0.87
Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation (1992) 0.85
Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass. Circ Res (1989) 0.84
Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol (2011) 0.84
Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J (1998) 0.82
Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol (2002) 0.81
Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man. Eur J Clin Pharmacol (1989) 0.80
Enalapril in the treatment of mild-to-moderate heart failure in general medical practice: a prospective and multicentre study concerning 17,546 patients. Acta Cardiol (1995) 0.80
Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure. Am J Physiol (1994) 0.78
Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Eur J Heart Fail (2000) 0.77
Significance of atrial natriuretic factor in chronic heart failure. Br J Hosp Med (1988) 0.77
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell (2005) 21.01
Cardiac resynchronization in chronic heart failure. N Engl J Med (2002) 17.52
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr (2010) 13.12
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature (2012) 4.84
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J (2004) 3.65
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J (2005) 3.50
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 3.36
Systolic and diastolic mechanics in stress cardiomyopathy. Circulation (2014) 3.36
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail (2005) 3.26
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med (2013) 3.09
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA (2007) 2.90
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther (2006) 2.85
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol (2008) 2.72
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol (2008) 2.66
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 2.65
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol (2007) 2.62
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Person-centered care--ready for prime time. Eur J Cardiovasc Nurs (2011) 2.49
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation (2007) 2.41
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation (2005) 2.39
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation (2005) 2.31
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol (2012) 2.31
Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol (2010) 2.29
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J (2012) 2.29
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging (2008) 2.24